Chronic GvHD MUD HCT for AML Despite Tacrolimus/Methotrexate Prophylaxis

Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.

Discussing the appropriateness of the initial therapy based on the NCCN guidelines for the given patient case.

Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.

Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.

Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.

Discussing how various treatments for chronic GvHD impact quality of life in terms of disease response and side effects.

Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.

Discussing perspectives on the future landscape of chronic GvHD management, including limitations of current targeted treatment options and emerging research of interest.